Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 17Recurrence 9Lymphoma, Large B-Cell, Diffuse 7Endometrial Neoplasms 4Lymphoma, T-Cell, Peripheral 3Glioblastoma 3Colorectal Neoplasms 3Sarcoma 2Primary Myelofibrosis 2Neoplasms 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Carcinoma, Squamous Cell 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Richter's Transformation 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasms by Site 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 17Bortezomib 11pomalidomide 10carfilzomib 6Lenalidomide 4imetelstat 3fludarabine 3daratumumab 3Standard of Care 3Panobinostat 3venetoclax 2siltuximab 2elotuzumab 2Cyclophosphamide 2Arsenic Trioxide 2spartalizumab 1shark cartilage extract 1selinexor 1saracatinib 1ricolinostat 1resiquimod 1poly ICLC 1plitidepsin 1pembrolizumab 1pazopanib 1motexafin gadolinium 1marizomib 1liposomal doxorubicin 1lestaurtinib 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × selinexor × Clear all
NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

US Oncology Research

Phase 2 Active not recruiting
73 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡